Neurocrine Biosciences reported quarterly EPS of $1.94, beating the $1.68 Zacks consensus by $0.26, or about 15.5%. Earnings also rose sharply from $0.08 per share a year ago, indicating a significant year-over-year improvement in profitability. The headline is a positive earnings surprise for the biotech company and could modestly support the stock.
Neurocrine Biosciences reported quarterly EPS of $1.94, beating the $1.68 Zacks consensus by $0.26, or about 15.5%. Earnings also rose sharply from $0.08 per share a year ago, indicating a significant year-over-year improvement in profitability. The headline is a positive earnings surprise for the biotech company and could modestly support the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.42
Ticker Sentiment
